Financial Projections - The company's operating revenue for 2024 is expected to be ¥167,254,775.41, a decrease of 12.34% compared to the previous year[4] - Total profit is projected to be ¥58,702,509.20, reflecting a decline of 23.24% year-over-year[4] - Net profit attributable to shareholders is expected to be ¥41,995,464.79, down 27.85% from the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be ¥28,632,556.95, a decrease of 31.91% year-over-year[4] - Basic earnings per share are expected to decline by 26.56% to ¥0.47[4] Assets and Equity - Total assets at the end of the reporting period are expected to be ¥646,468,267.93, an increase of 5.76% from the beginning of the period[6] - Shareholders' equity attributable to the company is projected to be ¥539,607,992.17, a slight increase of 0.39%[6] Performance Factors - The decline in performance is primarily attributed to reduced industry demand and adjustments in production capacity[7] - The company has optimized production schedules to match market demand, leading to increased unit product costs[7] Financial Caution - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[8]
新芝生物(430685) - 2024 Q4 - 年度业绩